Today's Treatment Blood and Neoplastic Diseases
Treatment of the Lymphomas G. HAMILTON FAIRLEY, J. E. FREEMAN British Medical journal, 1974, 4, 761-765 The term lymphoma is used to describe those primary malignant diseases of lymphoreticular tissue which usually arise in lymph nodes, the diagnosis being made by microscopic examination of biopsy material. The precise histological type is important and a simple classification on which treatment is based is shown in table I. Several diseases have been omitted, such as macroglobulinaemia, because they are discussed in other articles in this series, and the problem of the relationship between these diseases and leukaemia will not be discussed. The importance of this simple scheme is that it enables the patients to be grouped into those likely to have a good prognosis and those in whom the prognosis is very poor-which in turn has a bearing on the type of treatment to be used. Hodgkin's disease will be discussed first because the situation here is more clearly understood than with the other lymphomas. Cancer Research, 1971 Research, , 31, 1860 (1) An accurate assessment of the extent of disease-that is, the staging of the disease (table II) .
(2) A correct assessment of the risk that clinically undetected disease is present. This requires knowledge of the influence and the inter-relationship of sex, age, histological type, and the presence of systemic symptoms on the behaviour of the disease. In general, being male, elderly, or having mixed cellularity or lymphocytic depletion means that the disease is often more widespread and the prognosis worse than in women, younger patients, and those with lymphocytic predominant or nodular sclerosis.
(3) The treatment of all involved node regions in continuity by irradiation dose of 3,500-4,000 rads over four weeks, which is sufficient to destroy all tumour tissue yet well tolerated by the large volumes of normal tissues inevitably included.
With the advent of supervoltage equipment in the 1950s, particularly the linear accelerator, powerfully penetrating and accurately directed beams of x-rays became available which could be precisely shaped to cover the lymph-node regions above or below the diaphragm en bloc with better shielding of normal tissues from the main radiation beam. Thus, when disease involves supradiaphragmatic or infradiaphragmatic node groups, the so-called "mantle" or "inverted-Y" techniques are used, respectively. A recent analysis of patients treated at St Bartholomew's Hospital with the MVPP regimen showed that if the patients had never received chemotherapy in the past, complete remissions were obtained in 84%, and 78% would be alive at five years. Nevertheless, with patients who had previously been given "old-fashioned" treatment using single drugs continuously, 43% obtained a complete remission and only 36% would be alive at five years. The reason for this is that continuous treatment damages the bone marrow, making it impossible to give adequate combination chemotherapy. It is essential that when the decision to use chemotherapy is made quadruple therapy should be given from the start, and continuous singledrug treatment should not be tried first.
An additional problem is what to do with the small percentage of patients who do not respond to treatment and those who relapse. Unfortunately, other drugs are not very effective, but combinations of bleomycin with BCNU (a drug produced by the N.C.I., Bethesda), may produce transient improvement, though rarely complete remission of the disease.
Non-Hodgkin's Lymphoma The principles of treatment of non-Hodgkin's lymphoma are the same as for Hodgkin's disease, with radiotherapy for localized, and chemotherapy for generalized disease. There are, however, considerable practical differences for two reasons; firstly, the behaviour and prognosis vary with the different histological types; secondly, the pattern of recurrence is not predictable as it is in Hodgkin's disease, making it difficult to know how extensive fields of radiotherapy should be.
RADIOTHERAPY
In general, this group of diseases is very responsive to radiotherapy, but treatment policies are determined principally by the histological variety of the particular disease, its site, and extent of involvement.
Group 1-Follicular Lymphoma and Well-differentiated Lymphocytic Lymphoma In this more favourable histological group (table I), the diseases have a slow rate of growth and the prognosis in many patients is good. As with Hodgkin's disease, localized disease is appropnately treated by radiotherapy, which can be curative, or may at least defer the onset of disseminated disease. Radiation doses of 3,500 rads in four weeks can eradicate disease, provided that its full extent is adequately covered. Localized disease within this group is often found in certain sites within the head and neck, such as the orbit, paranasal sinuses, nasopharynx, tonsil, or base of tongue, and regional radiotherapy at these sites including the adjacent uninvolved lymph-node groups can cure a substantial proportion of such patients, over half at some sites.
In certain less common sites such as the stomach or testicle, a major surgical procedure is first required to establish the diagnosis and with the help of lymphography to assess the presence and extent of regional node disease; wide-field radio-763 therapy may then be planned with the intent to cure. Follicular lymphoma confined to the lymph nodes may often be controlled for many years with irradiation of the lymph-node groups in continuity, even with involvement above and below the diaphragm by using wide-field radiotherapy as in Hodgkin's disease.
Group 2-Poorly Differentiated Lymphocytic Lymphoma and Histiocytic Lymphoma
This group of diseases often presents with widespread disease, clearly beyond the scope of radiotherapy. Even when the disease is apparently well localized, however, radiotherapy commonly fails because of early relapse at distant sites or the development of generalized disease. The role of radiotherapy in this group is thus much less well defined. The combination of local radiotherapy followed by chemotherapy is a rational approach which is under investigation. In patients with widespread disease radiotherapy may best be used as an adjuvant to chemotherapy, by producing rapid shrinkage of bulky and distressing local tumour masses, or relieving local discomfort at sites of relapse if the disease becomes refractory to chemotherapy.
With the use of more effective combination chemotherapy regimens in this group of diseases, more patients are being rendered disease free, but a high incidence of later central nervous system relapse is now being seen, similar to earlier experience in acute lymphoblastic leukaemia. Steroids are also of use in these patients, and play a much more important part in management than in Hodgkin's disease. They have at least two specific actions: they frequently cause regression of lymph-node masses and organ infiltration (the socalled lympholytic effect); and they are of great value in the presence of anaemia and thrombocytopenia, probably because there is nearly always reduced survival of red blood cells and platelets. Our policy is to start with a dose of prednisolone at 40mg/day/adult, and reduce this as rapidly as possible, stopping whenever this is feasible.
The alternative is to take a more aggressive approach to treatment, giving one of the combinations mentioned in the next section, such as cyclophosphamide, vincristine, and prednisolone-but the value of this is still being investigated.
Group 2
The prognosis in poorly differentiated lymphocytic lymphoma and histiocytic lymphoma ( There is little value in an article such as this for giving details of the combinations under investigation becuase they change all the time depending on the results of the preliminary studies.
It is better to recommend that when doctors are faced with such patients they should contact their nearest centre specifically interested in such problems for the latest information. Indeed, there is an argument for all such patients to be referred to special centres because only in this way will enough be learnt to improve the progress of the diseases.
Complications of Treatment

RADIOTHERAPY
Like surgery, curative radiotherapy always damages some normal tissue, but in Hodgkin's disease the immediate effects are usually mild and so well tolerated that many patients can be treated as outpatients. Epilation of the occipital scalp, soreness, and pigmentation of the axillary and cervical skin, and mild oesophagitis usually develop during "mantle" irradiation, but the cutaneous and mucosal reactions recover quickly and full re-growth of scalp hair is seen within four to six months.
The "inverted-Y" technique may cause mild gastrointestinal symptoms, such as loss of appetite, nausea, and occasionally diarrhoea but can usually be easily controlled. Appreciable bone-marrow suppression may occur when the mantle and inverted-Y techniques are applied consecutively, but a rest of three to four weeks between courses of treatment permits marrow recovery and reduces the risk of low blood counts interfering with the second course of treatment.
The later potential complications of radiotherapy are particularly important, because many patients can now be cured. Their incidence and severity are reduced by scrupulous planning and protection of sensitive tissues. After mantle irradiation, apical and paramediastinal pulmonary fibrosis may be detected radiologically, but this rarely causes symptoms. A syndrome of acute transient radiation myelopathy may follow irradiation of the cervical spinal cord after a variable latent interval-with electrical paraesthesiae on neck flexion in the lumbosacral segments, upper limbs, or trunk-but always completely recovers.
Whenever inguinal and pelvic nodes are treated, the gonads of both sexes can be shielded from the direct radiation beam, but appreciable gonad doses from scattered radiation are unavoidable and may lead to infertility and amenorrhoea in about half of young women. The lower testicular doses received rarely interfere with sexual function, though the risk of congenital abnormalities in the offspring is thus theoretically increased.
CHEMOTHERAPY
Nearly all drugs used in the treatment of the lymphomas are toxic to the bone marrow, the exceptions being prednisone, bleomycin, and to some extent asparaginase. In addition they have individual specific effects which are of considerable importance. Bone marrow toxicity is undoubtedly the major worry, being most definite in patients who have received much treatment, whgther it be total nodal radiotherapy, or continuous drug chemotherapy, in the past. All patients must have regular blood counts, including platelet counts, but this group must be followed with special care, because it is a tragedy to lose a patient from the effects of treatment which has successfully eradicated the disease.
Uric-acid nephropathy is a potential hazard whenever malignant tissue is being destroyed and the use of allopurinol as, a routine starting 24-48 hours before treatment is a wise precaution against this complication. The only thing which must be remembered is that this drug potentiates the action of 6-mercaptopurine, whose dose may have to be modified if allopurinol is being given.
Space precludes a detailed analysis of all the complications of the drugs used for chemotherapy, but table VI lists some of the major systems of the body which may be affected. Since many of the diseases can also give rise to similar syndromes it is sometimes difficult to elucidate whether they are due to disease or cytotoxic therapy-for example, jaundice, renal failure, etc. Alopecia is common with modem combination chemotherapy, particularly when doxorubicin (adriamycin), cyclophosphamide, vin-cristine, and 5-fluorouracil are used. Because alopecia affects the patients' appearance it has been regarded as a serious side effect and has inhibited some people from using these drugs, particularly in combination. Nevertheless, the situation must be seen in true perspective. Firstly, if patients are warned that they will go bald and a suitable wig ordered before they lose their hair, most will accept the situation. Conversely, if they are not warned confidence may be lost and great distress caused. Secondly, alopecia is a small price to pay for successful chemotherapy leading to a return to normal health, but a high price if the chemotherapy is unsuccessful. Probably the most difficult decision in the management of the lymphomas is to know when to stop treatment.
Finally, it is important to realize that when doses are published in combination regimens these represent what it is aimed to give-that is, it is the maximum that is given. Frequently one gives less, usually because of marrow toxicity, and individual idiosyncratic reactions.
Conclusion
The treatment of the lymphomas, together with the leukaemias, represents one of the most exciting areas in cancer today. Improvements in radiotherapy and chemotherapy have created a situation where a significant percentage of patients, whether they present with localized or generalized diseasey may be restored to health for many years-if not cured. Others are less fortunate but the situation is challenging and it is hoped that present research will not only improve the progress for these patients but the lessons learnt in these diseases may benefit patients suffering from other forms of malignant disease.
Any Questions?
We publish below a selection of questions and answers of general interest
Amphetamines and Intellectual Ability
Is there any evidence that the long-term use of amphetamines reduces intellectual ability?
There is no clear evidence that the long-term use of amphetamines reduces intellectual ability, bu-t in one study of individuals taking high doses of amphetamines, one third said that their memory or their ability to concentrate had been impaired. No testing was done in this study to determrine the possibility of permanent brain damage.' Several investigators have suggested that recovery from the major effects of chronic use of lar,ge amounts of amphetamines taken intravenously is slow but complete, requiring perhaps six to 12 months of abstinence.'-' One study with monkeys employing high doses within the range consumed by some chronic human users produced evidence of significant cardiovascular change and permanent neurological damage after only a few weeks of daily drug administration.4 Further research will -be needed before a definitive answer could be given to this question. 
